How to prepare investigational drug labeling

What does FDA require on a human investigational drug label?

Section 312.6(a) requires the specified investigational-use caution on the immediate package. Paragraph (b) prohibits false or misleading labeling and representations that the drug is safe or effective for the use under investigation. Prepare a controlled, readable proof tied to the actual supply and study records. The narrow stockpile provision in paragraph (c) is not a general exception for small packages or blinded trials.

Before you begin

Human investigational drug labeling under 21 CFR 312.6. Commercial labels, multinational requirements and the narrow authorized stockpile exception require separate assessment.

What you will prepare: A reviewed label specification tied to the protocol, product, supply configuration and applicable investigational statement.

Use the actual investigational-label rule

Section 312.6(a) prescribes the investigational-use caution for the immediate package; copy the applicable statement from the current provision and have the regulatory owner verify it. Section 312.6(b) prohibits false or misleading labeling and claims that the investigational drug is safe or effective for the use being investigated. The specific exception procedure in paragraph (c) is not a general waiver for small labels or blinded studies.

Reconcile the label with supply and study controls

Create a specification identifying the study/product, package configuration, version and responsible approvers. Confirm the information needed by dispensing staff, storage and handling evidence, and any blinding constraints with the study and quality owners. Check that identifiers match the actual supply system. If the label must serve several countries, record each jurisdiction’s assessed requirement separately; a US warning alone is not a global label specification.

Review the printed proof and its use

Inspect actual-size proofs, including line breaks and overprinting. Test whether the intended user can distinguish kit or batch identifiers without inadvertently revealing treatment assignment. The protocol and dispensing instructions should explain use; the label should not introduce a new administration regimen. Document missing stability, storage or expiry decisions as unresolved inputs instead of filling in a plausible value.

Fictional example: a promotional phrase on trial supply

A draft adds “proven effective” to a carton used in an investigational study. Remove that unsupported representation and send the intended wording through the investigational-label review. If the change instead concerns an assigned expiry date, obtain the quality decision and supporting records; deleting promotional language does not validate the rest of the label.

Separate the prescribed caution from the supply specification

The wording in 21 CFR 312.6(a) is: “Caution: New Drug—Limited by Federal (or United States) law to investigational use.” Use the applicable regulatory wording in the controlled label specification; a shortened slogan such as “research use only” is not the statement prescribed by this provision. The text refers to the immediate package, so checking only an outer shipping carton can miss the relevant label.

Treat the following as an editorial review record. Some entries concern the practical supply workflow rather than additional label fields imposed by 312.6 itself.

Inspect the actual-size proof after variable data are applied. A blank artwork template can be legible while a long identifier obscures the caution or makes two fields indistinguishable. Review the package in its intended orientation and check the relationship between container and outer packaging. Route a conflict back to its source record; do not fix a printed number without identifying whether the specification, supply data or rendering step was wrong.

Fictional release exercise: the approved artwork passes review, but the packaging proof adds a treatment-specific abbreviation beside the kit identifier. The clinical team confirms that it would reveal assignment in this blinded study. Resolve the design and variable-data rule, then inspect representative proofs for both study supplies. Deleting the abbreviation from one PDF while leaving the printing rule unchanged would allow the problem to recur. No particular masking technique is universally sufficient; the actual study design governs the assessment.

Paragraph (c) concerns specified lots, batches or units of human drug product included or intended for inclusion in the Strategic National Stockpile. An appropriate FDA Center Director may grant the specified exception or alternative under the referenced procedures, within the provision's statutory limit. A sponsor's packaging preference, small-container constraint or blinding plan does not itself grant that exception.

Use the investigator-brochure guide for evidence and investigator communication. Keep operational label review distinct from a commercial carton/container review. This US guide does not establish the required label wording, language or clinical-supply fields for Health Canada, the EU or another authority.

Frequently asked questions

Sources and revisions

Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.

Related guides